These two are the closest pair on this site’s axis: both are recorded as GHRH analogs, both clear in minutes rather than days, and both are sold by the same telehealth companies off the same menus. What separates them is not pharmacology. It is that one of them has an FDA-approved product on the market and the other had one and lost it — and that the market these records describe has gone almost entirely the other way.
Tesamorelin is recorded here as approved (Egrifta SV) and Sermorelin as withdrawn. Those are two different facts and the difference matters: sermorelin is not a molecule that was never approved. It held approvals, and they were withdrawn in 2009 after the products were discontinued — the Federal Register notice says the withdrawal was not for reasons of safety or effectiveness. “Never approved” would be false about it, and “withdrawn” is the word the record supports.
What that leaves is a live approval on one side and a lapsed one on the other. Neither of those tells you which molecule is right for anybody. An unapproved molecule is not thereby a bad one and an approved one is not thereby better for you — the status is a fact about a regulatory record, and interpreting it for your situation is a clinician’s job.
Here is the awkward part, and this site prints it rather than smoothing it over. The molecule with the approved product is the one whose half-life this site cannot state. Sermorelin’s figure carries a document. Tesamorelin’s renders a [needs citation] marker wherever it appears, including on the axis below.
It is not a gap in the looking. Three FDA labels for tesamorelin give three different half-lives and the only thing separating them is the face date printed on each one, so citing any single label would attach a real document to a figure the other two contradict. The recorded value is also not a range: it is two population point estimates — one in healthy subjects, one in patients — printed as though somebody had measured a span. On a site whose organising rule is that ranges stay ranges, publishing that under a citation would be the exact failure it exists to name.
So the marker stays until the record can hold what the documents actually say. It is one of 3 claims across the 5 molecules still in that state, all of them listed and explained on the sources page, and it is part of why this site does not claim its own axis is fully sourced.
Attributes down, molecules across, both columns kept at every screen width. A cell reading “not recorded” is a statement about this site’s records rather than a claim about the molecule, and it takes no citation marker for that reason — what would settle it is us doing the work, not a reference.
| Attribute | TesamorelinTES | SermorelinSER |
|---|---|---|
| Mechanism | GHRH analog Dominikowski et al. 2026 | GHRH analog Esposito et al. 2003 |
| Half-life | 26–38 min [needs citation] | 10–20 min Esposito et al. 2003 |
| Cortisol / prolactin | not recorded | not recorded |
| FDA status | approved (Egrifta SV) EGRIFTA SV label, revised 03/2024 | withdrawn FDA, 78 FR 14095 (2013) |
| Reported use | 2 mg once daily Dominikowski et al. 2026 | 200–300 µg once daily, typically before bedtime Dominikowski et al. 2026 |
| What sellers publish | 2 figures read1 standing rate, 1 floor — quoted against 1 billing cycle. 0 of the 2 say what dose the money buys. A floor is where the pricing starts, not what anyone pays. Not a range, because these are not the same measurement. | 11 figures read5 standing rates, 4 floors, 1 prepaid total, 1 introductory price — quoted against 7 different billing cycles. 3 of the 11 say what dose the money buys. A floor is where the pricing starts, not what anyone pays. Not a range, because these are not the same measurement. |
The reported-use row describes self-reported protocols recorded in the peer-reviewed literature — the review that carries them labels its own table anthropological and behavioural data drawn from forums, not clinical recommendations. It is not prescribing information, and it is not a census of what sellers sell.
This is the part a comparison of two molecules does not show you. 14 of the 14 sellers whose pages this site has read list sermorelin. 3 list tesamorelin. The molecule with the live approval is on 3 of 14 of these menus; the one whose approval lapsed is on every one of them.
This site does not know why, and it is not going to guess: nothing in these records says anything about cost of goods, prescribing patterns, or what a compounder can obtain. What the records do say is what is on the shelves that were read, on the dates recorded beside each figure — and on those shelves the approved molecule is the rare one.
Sellers listing Sermorelin
14 of 14
11 of the site's figures buy it on its own, against 7 different billing cycles.
Sellers listing Tesamorelin
3 of 14
2 figures buy it on its own; a further 2 name it inside a pairing.
Tesamorelin figures that state a dose
0 of 2
Not one of them. The literature records 2 mg once daily as the reported use, and there is nothing here to check that against.
Sermorelin figures that state a dose
3 of 11
The molecule with the deeper roster is also the only one of the two with any stated dose at all.
Counted from the 14 records behind the board, every figure read off the seller’s own page and dated. The per-seller working is on the seller records.
Every figure this site holds for these two molecules, with the qualifier that makes it mean something: what kind of number it is, what period it is charged for, what dose it buys, and the day it was read. Grouped by molecule, not ordered by size — a floor, a standing rate, a prepaid total and an introductory price are four different measurements. Nothing here names a cheapest.
The board scrolls sideways; the seller column and the button column both stay put.
| Seller | What the figure buys | Figure | What it is | Charged | Dose | Go |
|---|---|---|---|---|---|---|
| ElitePhysiqMD | Sermorelin“Sermorelin” | $267.30Checked September 2026 | standing rate | per month | dose not stated | Open listing → |
| Tesamorelin“Tesamorelin” | $274.50Checked September 2026 | standing rate | per month | dose not stated | ||
| TesamorelinIpamorelin“Tesamorelin / Ipamorelin” | $274.50Checked September 2026 | standing rate | per month | dose not stated | ||
| Longevixx | Sermorelin“Sermorelin” | from $249Checked September 2026 | floor | per month | dose not stated | Open listing → |
| Tesamorelin“Tesamorelin” | from $299Checked September 2026 | floor | per month | dose not stated | ||
| TesamorelinIpamorelin“Tesamorelin / Ipamorelin” | from $349Checked September 2026 | floor | per month | dose not stated | ||
| Oak Longevity | no figure we can publishthe two figures render inside the order flow, each struck through and replaced, with a promotional code shown as applied — so what is on screen is a discounted checkout price, not a standing rate anyone is quoted before starting.Checked September 2026 | Open site → | ||||
| Youth & Soul | SermorelinIpamorelin“Growth Hormone Optimization” — also buys NAD+ sublingual tablets (250mg); Methylene Blue; IGF-1 & hormone panel blood work review; physician monitoring & dose optimization | $149Checked September 2026 | standing rate | per month | dose not stated | Open listing → |
| Liberty | Sermorelin“Sermorelin — 1 Month” | $116Checked September 2026 | standing rate | per month | 200–500 µg nightly at bedtime, escalating by phase | Open listing → |
| WePeptideRx | Sermorelin“Compounded Sermorelin — 28-Day Supply” | $249Checked September 2026 | standing rate | per 28-day supply | 0.75, 2.25 or 3 mg per week — the same price at every dose | Open listing → |
| PeterMD | Sermorelin“Sermorelin — 4-Week Supply” | $211.65Checked September 2026 | standing rate | per 4-week supply | dose not stated | Open listing → |
| Joi + Blokes | Sermorelin“Sermorelin Peptide Therapy — Subscribe + Save” | $559Checked September 2026 | prepaid total | per 12-week supply | injections or troches; dose not stated | Open listing → |
| System Labs | Sermorelin“Sermorelin” | $109Checked September 2026 | introductory price | first month | monthly supply, 9 mg | Open listing → |
| Sermorelin“Sermorelin” | $219Checked September 2026 | standing rate | per month | dose not stated | ||
| CoreAge Rx | Sermorelin“Sermorelin” | from $99Checked September 2026 | floor | per month | dose not stated | Open listing → We may be paid if you sign up through this link. |
| Invigor Medical | Sermorelin“Sermorelin Injections” | from $220Checked September 2026 | floor | cycle not stated | dose not stated | Open listing → |
| Luvo Health | Sermorelin“Sermorelin” | from $27Checked September 2026 | floor | per week | dose not stated | Open listing → |
| VigorMeds | no figure we can publishthe page prints two different floors for the same listing — “from $149 per month” on the product grid and “from $199” on the catalogue’s own finder deck, for the same product — and the $50 between them is the size of a “$50 off first order” badge that neither figure says is already applied.Checked September 2026 | Open listing → | ||||
| Vytora Health | no figure we can publishthe page contradicts itself: the buy panel and the page's own FAQ give different monthly figures for the same plan, and nothing on the page says which is current.Checked September 2026 | Open listing → | ||||
Read off each seller’s own page and dated in the row. Nothing here is scored or ranked; the ordering is the order the records are written in lib/providers.ts.
US dollars, exactly as each seller prints them — one axis, 7 different billing cycles and 4 different kinds of figure.
ElitePhysiqMD — “Sermorelin”
$267.30
a standing rate · per month — dose not stated
ElitePhysiqMD — “Tesamorelin”
$274.50
a standing rate · per month — dose not stated
Longevixx — “Sermorelin”
from $249
a floor, not a rate · per month — dose not stated
Longevixx — “Tesamorelin”
from $299
a floor, not a rate · per month — dose not stated
Liberty — “Sermorelin — 1 Month”
$116
a standing rate · per month — 200–500 µg nightly at bedtime, escalating by phase
WePeptideRx — “Compounded Sermorelin — 28-Day Supply”
$249
a standing rate · per 28-day supply — 0.75, 2.25 or 3 mg per week — the same price at every dose
PeterMD — “Sermorelin — 4-Week Supply”
$211.65
a standing rate · per 4-week supply — dose not stated
Joi + Blokes — “Sermorelin Peptide Therapy — Subscribe + Save”
$559
a total, paid up front · per 12-week supply — injections or troches; dose not stated
System Labs — “Sermorelin”
$109
an introductory price · first month — monthly supply, 9 mg
System Labs — “Sermorelin”
$219
a standing rate · per month — dose not stated
CoreAge Rx — “Sermorelin”
from $99
a floor, not a rate · per month — dose not stated
Invigor Medical — “Sermorelin Injections”
from $220
a floor, not a rate · cycle not stated — dose not stated
Luvo Health — “Sermorelin”
from $27
a floor, not a rate · per week — dose not stated
13 single-molecule figures recorded from 10 sellers’ own pages, each with the date it was read, on the seller records.
Every pharmacological figure on this page is traced to a document below or marked as untraced. Seller figures are read off the seller’s own page and carry the date they were read.
Citation status, counted from the records behind this page rather than typed: 1 of 8 pharmacological figures on it is recorded in this site’s data but not yet traced to a published source, and it is marked [needs citation] where it appears. Where the writing below restates one of those figures, it rests on the same unsourced record. The open sourcing work is listed in the repository’s content to-do. This line counts itself down as sources land.
4 documents are cited on this page, listed in the order the figures above rely on them. Each carries the date printed on the document itself, which is not the date it was read and not the date in its address.
3 of this site’s 14 seller records carry more than one of Tesamorelin, Sermorelin — which is the only reason they are listed here rather than everyone we have read. 0 of them pay us a commission; 3 do not. Which is which is on each seller’s own record and, counted, on the disclosure page. Their figures, with every qualifier attached, are in the board above.
Prices four listings across three of these molecules on one catalogue page and states a dose on none of them. Tesamorelin alone and tesamorelin with ipamorelin carry the identical figure, which is the clearest thing on the page: adding a second molecule changes the price by nothing. The catalogue also prints “Save 10% with subscription” beside the figures.
Every figure on this catalogue is a floor — the page prints “from” in front of all of them — and none states a dose, so the gaps between the four are gaps between starting points, not between what anyone pays. The CJC-1295 listing is sold only as a pairing and never says which form of CJC-1295 it contains.
The strongest single illustration on this site of the problem it exists to describe: sermorelin and tesamorelin are offered side by side in one medication picker, at the same struck-through figure and the same discounted figure, over the same supply. Two molecules whose recorded half-lives differ by roughly an order of magnitude, priced as though the choice between them were a flavour.